These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 35830996)

  • 1. The outcome of rituximab in treating steroid dependent nephrotic syndrome.: Histopathology and immunosuppressive drugs as predicting factors.
    Al Salloum AA; Al Herbish AJ; Al Hissi MA; Abdalla MS; Salim SB; Farhat AH; Shagal RA; Othman A; Alshaiban A; Temsah MA; Al-Eyadhy AA; Alhasan KA
    Saudi Med J; 2022 Jul; 43(7):760-764. PubMed ID: 35830996
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Study protocol: mycophenolate mofetil as maintenance therapy after rituximab treatment for childhood-onset, complicated, frequently-relapsing nephrotic syndrome or steroid-dependent nephrotic syndrome: a multicenter double-blind, randomized, placebo-controlled trial (JSKDC07).
    Horinouchi T; Sako M; Nakanishi K; Ishikura K; Ito S; Nakamura H; Oba MS; Nozu K; Iijima K
    BMC Nephrol; 2018 Nov; 19(1):302. PubMed ID: 30382824
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of rituximab therapy in children with refractory nephrotic syndrome: a prospective observational study in Shanghai.
    Sun L; Xu H; Shen Q; Cao Q; Rao J; Liu HM; Fang XY; Zhou LJ
    World J Pediatr; 2014 Feb; 10(1):59-63. PubMed ID: 24464665
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rituximab in childhood steroid-sensitive nephrotic syndrome: are multiple subsequent courses safe and effective?
    Subun C; Suwannahitatorn P; Webb H; Tullus K
    Arch Dis Child; 2021 Jul; 106(8):815-818. PubMed ID: 33177054
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Treatment of children with steroid-dependent nephrotic syndrome with rituximab].
    Huang J; Du J; Wang S; Xiao L; Zhao X
    Zhonghua Er Ke Za Zhi; 2014 Jul; 52(7):521-4. PubMed ID: 25224058
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predictive factors of long-term disease remission after rituximab administration in patients with childhood-onset complicated steroid-dependent nephrotic syndrome: a single-center retrospective study.
    Ohyama R; Fujinaga S; Sakuraya K; Hirano D; Ito S
    Clin Exp Nephrol; 2023 Oct; 27(10):865-872. PubMed ID: 37477752
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predictors of relapse and long-term outcome in children with steroid-dependent nephrotic syndrome after rituximab treatment.
    Fujinaga S; Hirano D; Mizutani A; Sakuraya K; Yamada A; Sakurai S; Shimizu T
    Clin Exp Nephrol; 2017 Aug; 21(4):671-676. PubMed ID: 27558467
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of low-dose rituximab in minimal change disease and prevention of relapse.
    Zhang J; Zhao H; Li X; Qian R; Gao P; Lu S; Ma Z
    BMC Nephrol; 2023 Apr; 24(1):112. PubMed ID: 37101300
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rituximab in children with steroid-dependent nephrotic syndrome: experience of a tertiary center and review of the literature.
    Van Horebeek I; Knops N; Van Dyck M; Levtchenko E; Mekahli D
    Acta Clin Belg; 2017 Jun; 72(3):147-155. PubMed ID: 27409338
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rituximab in adult patients with immunosuppressive-dependent minimal change disease.
    Hoxha E; Stahl RA; Harendza S
    Clin Nephrol; 2011 Aug; 76(2):151-8. PubMed ID: 21762648
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Incidence of hypogammaglobulinaemia in children with steroid-dependent/frequently relapsing nephrotic syndrome treated with rituximab and its association with severe infections].
    Zhi YZ; Cao L; Ying DJ; Dou WJ; Gu R; Zhang JJ
    Zhonghua Yi Xue Za Zhi; 2024 Feb; 104(6):433-439. PubMed ID: 38326055
    [No Abstract]   [Full Text] [Related]  

  • 12. Rituximab in steroid-dependent idiopathic nephrotic syndrome in childhood--follow-up after CD19 recovery.
    Sellier-Leclerc AL; Baudouin V; Kwon T; Macher MA; Guérin V; Lapillonne H; Deschênes G; Ulinski T
    Nephrol Dial Transplant; 2012 Mar; 27(3):1083-9. PubMed ID: 21810762
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term outcome of childhood-onset complicated nephrotic syndrome after a multicenter, double-blind, randomized, placebo-controlled trial of rituximab.
    Kamei K; Ishikura K; Sako M; Aya K; Tanaka R; Nozu K; Kaito H; Nakanishi K; Ohtomo Y; Miura K; Takahashi S; Morimoto T; Kubota W; Ito S; Nakamura H; Iijima K;
    Pediatr Nephrol; 2017 Nov; 32(11):2071-2078. PubMed ID: 28664242
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rituximab in Children with Steroid-Dependent Nephrotic Syndrome: A Multicenter, Open-Label, Noninferiority, Randomized Controlled Trial.
    Ravani P; Rossi R; Bonanni A; Quinn RR; Sica F; Bodria M; Pasini A; Montini G; Edefonti A; Belingheri M; De Giovanni D; Barbano G; Degl'Innocenti L; Scolari F; Murer L; Reiser J; Fornoni A; Ghiggeri GM
    J Am Soc Nephrol; 2015 Sep; 26(9):2259-66. PubMed ID: 25592855
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Survey of rituximab treatment for childhood-onset refractory nephrotic syndrome.
    Ito S; Kamei K; Ogura M; Udagawa T; Fujinaga S; Saito M; Sako M; Iijima K
    Pediatr Nephrol; 2013 Feb; 28(2):257-64. PubMed ID: 23052656
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Maintenance therapy with mycophenolate mofetil after rituximab in pediatric patients with steroid-dependent nephrotic syndrome.
    Ito S; Kamei K; Ogura M; Sato M; Fujimaru T; Ishikawa T; Udagawa T; Iijima K
    Pediatr Nephrol; 2011 Oct; 26(10):1823-8. PubMed ID: 21556716
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risk factors for relapse and long-term outcome in steroid-dependent nephrotic syndrome treated with rituximab.
    Kamei K; Ogura M; Sato M; Sako M; Iijima K; Ito S
    Pediatr Nephrol; 2016 Jan; 31(1):89-95. PubMed ID: 26341251
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rituximab treatment for difficult-to-treat nephrotic syndrome in children: a multicenter, retrospective study.
    Taşdemir M; Canpolat N; Yıldız N; Özçelik G; Benzer M; Saygılı SK; Özkayin EN; Türkkan ÖN; Balat A; Candan C; Çelakıl M; Yavuz S; Akıncı N; Göknar N; Akgün C; Tülpar S; Alpay H; Sever FL; Bilge İ
    Turk J Med Sci; 2021 Aug; 51(4):1781-1790. PubMed ID: 33581711
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Retrospective single-arm cohort study of steroid-dependent minimal change nephrotic syndrome treated with very low-dose rituximab.
    Fujimoto K; Kagaya Y; Kumano S; Fujii A; Tsuruyama Y; Matsuura T; Yamazaki K; Nomura K; Okada K; Okino K; Adachi H; Furuichi K; Yokoyama H
    Clin Nephrol; 2021 Jan; 95(1):29-36. PubMed ID: 33074094
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Multicenter survey of diagnostic and therapeutic status in Chinese childhood patients with steroid-sensitive, relaping/steroid-dependent nephrotic syndrome].
    Working Group For National Survey On Status Of Diagnosis And Treatment Of Childhood Renal Diseases
    Zhonghua Er Ke Za Zhi; 2014 Mar; 52(3):194-200. PubMed ID: 24824389
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.